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Summary 
Recent  studies  have  established  that  interleukin  (IL)-10  induces  growth  and  most  notably 
differentiation of normal human B lymphocytes. We studied here the effects of IL-10 on the 
proliferation and survival of B-chronic lymphocytic leukemia (B-CLL) cells.  IL-10 was found 
to inhibit 54-96%  of the spontaneous tritiated thymidine incorporation observed in 3  of 12 
B-CLL samples.  Furthermore, IL-10 decreased the viable cell recovery of all five B-CLL samples 
tested, irrespective of whether cells were spontaneously synthesizing DNA or not. After 1 wk, 
B-CLL populations cultured with IL-10 were lost while those cultured without IL-10 survived. 
Flow cytometric analysis, DNA gel electrophoresis, and Giemsa staining all revealed that IL-10 
induced B-CLL cells to die from apoptosis.  This IL-10-mediated apoptosis was dose dependent 
and specific as it could be inhibited by a neutralizing anti-IL-10 antibody. B-CLL ceils undergoing 
apoptosis in response to IL-10  showed decreased Bcl-2 protein levels. Addition of IL-2, IL-4, 
interferon %  and anti-CD40 monoclonal antibody prevented the IL-10-mediated apoptosis of 
B-CLL cells.  None of the malignant B cell populations  obtained from eight non-Hodgkin's 
lymphomas and  three hairy cell leukemias underwent apoptosis  after IL-10 treatment,  thus 
suggesting that the apoptotic effect of IL-10 is specific for B-CLL cells.  Thus, IL-10 inhibits 
the DNA synthesis and most notably the survival of B-CLL ceils, findings that call for considering 
IL-10 in the immunotherapy of chemoresistant B-CLL. 
T 
he production of high affinity and high specificity anti- 
bodies is the result of multiple genetic alterations of the 
B lymphocyte immunoglobulin loci (1). These modifications 
occur at different stages of the B lymphocyte history, both 
in bone marrow and in the secondary lymphoid organs (2, 
3). These various events are sometimes accompanied by ab- 
normal B cell development resulting in multiple types of 
leukemias, one of the most common in Western countries 
being the B-chronic lymphocytic leukemia (B-CLL) 1 (4). 
The B lymphocytes involved in this disease express CD5 
antigen, surface IgM with or without IgD, CD23, and the 
bcl-2 protooncogene. A major fraction of the neoplastic popu- 
lation is frozen in Go phase of the cell cycle. For all these 
characteristics and on the basis  of morphological analysis, 
B-CLL cells have been considered to represent the neoplastic 
counterpart of the CD5  resting B lymphocytes (5) or the 
mantle zone-like B lymphocytes (6).  However, when con- 
sidering the responsiveness to cytokines, discrepancies between 
B-CLL cells and normal B cells have been observed in vitro. 
Indeed, while normal resting B cells need a first external ac- 
tivation signal to proliferate in response to IL-2, •50%  of 
Abbreviation used in this  paper: B-CLL, B-chronic  lymphocytic  leukemia. 
B-CLL cells show a spontaneous proliferative response to IL-2 
(7). Furthermore, IL-4 not only lacks growth-promoting ac- 
tivity on B-CLL cells, but displays  a potent inhibitory ac- 
tivity on their proliferation induced after surface Ig triggering 
with or without IL-2 (8). 
IL-10 has been found to enhance both the proliferation 
and the differentiation of normal B cells stimulated by cross- 
linking of either their surface Igs or their CD40  antigens 
(9,  10).  Recently, we have shown that IL-10 also induced 
the proliferation and the differentiation of anti-CD40 acti- 
vated B-CLL cells (11). In further studying the effects of IL- 
l0 on nonstimulated B-CLL cells we observed that it decreased 
their survival.  The present report demonstrates that IL-10 
specifically induces apoptotic cell death of nonactivated B-CLL 
cells. 
Materials  and Methods 
Antibodies.  The monoclonal and polyr  antibodies used for 
the phenotyping of the leukemic B cell preparations were purchased 
from the following manufacturers:  FITC-conjugated anti-CD5 (Leu 
1), anti-CD19 (Leu 12), anti-CD20 (Leu 16), anti-CD14 (Leu M3), 
anti-CD10 (Calla), and anti-HLA DR mAbs; all from Becton Dick- 
inson Monoclonal Center (Mountain View, CA); FITC-conjugated 
anti-CD3 (IOT3) and anti-CD2 (IOT11) mAbs both from Im- 
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and F(ab)'2 fragments of goat anti-human  IgM,  IgD,  IgA,  and 
IgG mAbs  (from Dako (Glostrup, Denmark);  FITC-conjugated 
F(ab)'2 fragments of donkey anti-human K or h light chains anti- 
bodies from Kallestad Laboratories (Austin, TX). The neutralizing 
anti-IL-10 rabbit polyclonal purified Ab was produced in the labo- 
ratory as described previously (12). 3/~g/ml of anti-IL-10 Ab were 
determined to totally inhibit the effect of 10 ng/ml of IL-IO in an 
inhibition assay of IFN-3r production (12). A polyclonal anti-C4 
Ab, produced and purified in the same conditions as the anti-IL-10, 
was  used as unrelated control antibody. 
Flow Cytometric Analysis.  Cell surface staining was performed 
as  described previously (11) and  samples  were analyzed with  a 
FACScan  |  (Becton Dickinson and Co., Sunnyvale, CA). Propidium 
iodide (2/~g/ml) was added in each sample before flow cytometric 
analysis in order to gate-out dead cells. The negative control was 
performed with an isotype-matched unrelated mAb. For intracel- 
lular detection of Bcl-2 protein, cells were permeabilized by 15- 
rain incubations at 4~  in saponine (0.5  mg/ml) before staining 
with anti-Bcl-2 mAb or an unrelated mAb as a negative control. 
Apoptosis was determined by measurement of the incorporation 
of DNA-binding fluorophores Bisbenzimide Hoechst 33342 (Beh- 
ring Diagnostics, La Jolla, CA) and propidium iodide as described 
previously (13). Cells were incubated 5 rain with 10/~M Hoechst 
33342  and 32/~M propidium iodide immediately before analysis 
with a double laser equipped FACStar  Plus  |  (Becton Dickinson 
and Co.). Analysis permitted us to delineate three different popula- 
tions: (a) permeable cell membranes allow dead cells to incorporate 
propidium iodide; (b) apoptotic cells incorporate only Hoechst; (c) 
viable cells incorporate neither propidium iodide nor Hoechst. The 
validity of this method was confirmed by fluorescent microscopy 
on the cells sorted from each population. 
Factors.  Purified recombinant IL-2 (3  x  106 U/mg; Amgen Bi- 
ologicals,  Thousand Oaks, CA), 1I.-4 (1  x  107 U/rag;  Schering- 
Plough Research  Institute, Kenilworth, NJ), and IFN-y (1  x  107 
U/mg; Genzyme Corp., Cambridge, MA) were routinely used at 
the final concentration of 20 U/ml,  100 U/ml,  and 500 U/ml, 
respectively. Recombinant highly purified IL-10  from Chinese ham- 
ster ovary transfected cells, was obtained from Schering-Plough Re- 
search Institute and routinely used at a final concentration of 100 
ng/ml. 
Patients.  Pathological samples were provided by Dr. A. Bussel 
(Hrpital Saint-Louis,  Paris, France),  Dr. J.  F.  Rossi  (Institut du 
CanceroVal d' Aurelle,  Montpellier, France),  Dr. A. Bryon (Hrp- 
ital Edouard Herriot, Lyon, France),  and Dr. J. J. Sotto (Hrpital 
A.  MichaUon,  Grenoble, France).  This study included eight pa- 
tients with the diagnosis  of B-CLL, eight with the diagnosis  of 
non-Hodgkin's lymphomas of  low grade malignancy,  according to 
the Working Formulation (14), and three with hairy cell leukemia. 
The available specimens included blood, spleen, and lymph nodes. 
Patient BAR was treated by corticoids and patient FLA was treated 
by chemotherapy at the time of the study. All other patients had 
not received any chemotherapy in  the 3 mo before this  study. 
Purification ofB Lympkocytes.  Organs were cut with a scalpel 
blade and passed through a fine wire mesh to prepare a single cell 
suspension. Mononuclear cells were separated by standard Ficoll/Hy- 
paque gradient method and were next submitted to E rosetting 
with sheep  red blood cells. Nonrosetting cells (E-fraction) were 
labeled  with anti-T cell (anti-CD2,  anti-CD3)  and anti-mono- 
cyte (anti-CD14) mAbs and subsequently incubated with magnetic 
beads  coated  with  anti-mouse  IgG  antibodies  (Dynal,  Oslo, 
Norway). Residual non-B cells were removed by applying a mag- 
netic field for 5 rain. 
B Cell Cultures.  B cells were cultured in RPMI 1640 enriched 
with 10% selected heat inactivated FCS, 100/~g/ml streptomycin, 
and 2 mM glutamine (all from Flow Laboratories,  Maclean,  VA), 
under a final volume of 100/~1 for proliferation assays and 500/xl 
for flow cytometric analysis or cell counts. Cytokines were added 
at the onset of the culture. For anti-CD40  activation,  1  x  106 
cells/ml of B-CLL cells were seeded together with the anti-CD40 
mAb 89 (0.5 #g/ml) and 5  x  104 cells/ml CDw32 transfected  L 
cells as previously described  (15). DNA synthesis  was determined 
by pulsing cells with  [3H]TdR for the final  16 h  of the culture 
period. 
Results 
IL-IO Inhibits Spontaneous DNA Synthesis and Decreases Viable 
Cell Recovery of B-CLL  Cells.  To examine the proliferative 
response of B-CLL cells to IL-10,  12 B-CLL samples were 
cultured for 3 d in complete medium with or without IL-10. 
Four B-CLL samples (Fig. 1 A) spontaneously incorporated 
significant amounts of [3H]TdR. (2,800-5,700  cpm) after 3 
d of culture, and in all four cases,  IL-10 significantly reduced 
this  response  (54-96%  inhibition).  As  shown  in  Fig.  1 B 
Figure  1.  Dose-dependent inhibitory factor effect of IL-10 on sponta- 
neous DNA  synthesis of B-CLL cells. 1  ￿  l0  s cells of the leukemic 
samples were cultured without or with (A) 100 ng/ml or (B) serial dilu- 
tions of IL-10. [3H]TdR  uptake was assessed  at day 3. Results are expressed 
as mean  _+  SD of triplicate determination. 
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tory activity of IL-10 was dose dependent. The 50% inhibi- 
tion was obtained with 1-3 ng/ml (depending on the sample) 
and maximal inhibition with 10-100  ng/ml of IL-10.  The 
IL-10 dependent inhibition of [3H]TdP, uptake was observed 
from days 2 to 7 (data not shown). The poor [3H]TdR up- 
take observed in the eight other B-CLL cases (~< 1,000 cpm) 
was not significantly affected by IL-10.  Trypan blue dye ex- 
clusion assays, performed on five B-CLL samples cultured for 
4 d with or without IL-10,  indicate that IL-10 reduces  the 
viability of B-CLL populations, irrespective of whether cells 
spontaneously synthesized DNA or not (Fig. 2 A). As illus- 
trated on Fig. 2 B, a significant decrease of  viable cell numbers 
was usually detected after 3 d, and after 7 d,  this resulted 
in the loss of the culture. The effect was specific, since a neu- 
tralizing anti-IL-10 antibody was able to prevent the IL-10-in- 
duced cell death. 
IL-IO Enhances the Apoptosis of B-CLL Cells.  To further 
document the deleterious effect of IL-IO on cell viability, we 
tested whether IL-10-treated B-CLL cells were dying through 
apoptosis. To this end, after a 24-h incubation with or without 
IL-10, B-CLL cells were incubated for 5 min with Hoechst 
33342 and propidium iodide to discriminate, by flow cytom- 
etry, cells undergoing apoptosis from viable cells and from 
necrotic cells, as described in Materials and Methods. As shown 
by FACS  |  analysis  (Fig.  3, A  and B),  IL-IO increased  the 
proportion of FLA B-CLL cells undergoing apoptosis,  from 
8 to 30%, as shown by a selective uptake of Hoechst 33342 
(lower right panel).  It also increased  the proportion of dead 
cells from 20 to 30%, as shown by the uptake of propidium 
iodide (upper  panel). To further confirm the relationship be- 
tween these three populations, double negative cells of the 
lower left quadrant, and cells incorporating Hoechst 33342 
of the lower right quadrant, were sorted, and recuhured for 
an additional 24 h, in complete medium without IL-10. After 
the second culture, the sorted Hoescht 33342  positive cells 
all incorporated propidium iodide (Fig. 3 C), indicating fur- 
ther loss of membrane integrity, most likely before cellular 
disintegration.  16% of the sorted cells, excluding both Hoechst 
33342  and propidium iodide, incorporated Hoechst 33342 
after recuhure (Fig. 3 D), thus indicating that the apoptotic 
process was engaged even though IL-10 was removed. On 
the 6 B-CLL samples tested, IL-10 enhanced by two- to four- 
Figure  2.  IL-10  decreases  viable  B-CLL  cell  recovery.  B-CLL  cells  were 
cultured in complete medium: (/1) without or with IL-10 (100 ng/ml) 
(Trypan blue dye exclusions  were performed  at day 3); (B) without (~) 
or with IL-10 (100 ng/ml) (~), anti-ILol0  (3/~g/ml) (A) or combination 
of anti-IL-10 and IL-10 (O) (Trypan  blue dye exclusions  were performed 
daily from days 0-7). Two experiments performed with other B-CLL 
samples yielded  similar  results. The symbol  "+" means that this sample 
spontaneously  incorporated  [3H]TdR which  is inhibited  by Ibl0 (see Fig. 
1 A). Others do not spontaneously  incorporate [3H]TdR. 
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Figure  3.  IL-10  increases the spontaneous  apoptosis  of B-CLL  cells. 5 
x  10  S  B-CLL  cells  were cultured  without or with 100 ng/ml of Ibl0. 
After 24 h, calls were incubated  during 5 rain with Hoechst 33342 (10 
/~M) and propidium  iodide  (32/~M). Discrimination  of necrotic  and apop- 
totic cells was performed  by muhiparametric  flow  cytometry.  Ordinates: 
propidium iodide; abscissa: Hoechst 33342. Numbers indicate the per- 
centage  of positive  cells  in the three  populations.  The upper quadrant  cor- 
responds to dead cells, the lower left  to viable cells and the lower right 
to apoptotic  cells. (,4) Complete  medium; (B) Ibl0; (C) apoptotic  cells 
sorted and recultured  for 24 h without Ibl0; (D) viable  cells, sorted and 
recultured for 24 h without IL-10. Table  1.  Effect  of lL-IO on  the Survival  of Malignant  B  Cells 
Percent  viability  Percent  apoptosis 
Phenotype  IL-10  IL-10 
Samples  CD5  CD10  slg*  -  +  -  + 
FLA  B-CLL*  +  -  ml  58  41  10  26 
PAS  B-CLL  +  -  Mk  67  45  4  14 
PIG  B-CLL  +  -  mdl  81  66  6  15 
PON  B-CLL  +  -  k  73  21  8  36 
VIS  B-CLL  +  -  MDk  25  8  26  34 
GER  B-CLL  +  -  MDk  36  16  ND  ND 
LES  B-CLL  +  -  mk  53  14  6  21 
BAR  B-CLL  +  -  M1  30  14  ND  ND 
GAN  DSCL  +  +  Mk  7  9  8  8 
VER  DSCL  +  -  MGkl  35  33  16  15 
MAG  SLL  +  -  MDk  57  56  9  10 
BOU  FML  -  +  Gk  32  36  9  7 
BILE  FML  -  +  MAk  88  87  1  1 
BOIL  FSCL  -  +  Gk  54  39  15  17 
MOI  FLCL  -  +  MDk  37  42  12  14 
IEN  FLCL  -  ND  ND  40  42  5  7 
MAU  HCL  -  +  mdk  63  59  3  4 
GOD  HCL  -  +  mkl  71  75  2  3 
MAIL  HCL  -  ND  M1  15  12  18  27 
* Lower case letter for low density expression of surface  Ig; upper case letters for high density surface  Ig. 
* SLL, small lymphocytic lymphoma; DSCL,  diffuse small cleaved lymphoma; FML, follicular  mixed lymphoma; FSCL,  follicular small cleaved lym- 
phoma;  FLCL,  follicular large cell  lymphoma; HCL,  hairy cell  leukemia. 
Figure  4.  IL-10  induces apoptosis of B-CLL cells. (A and B) Giemsa staining of B-CLL cells cultured for 48 h in medium alone (A) or with IL-10 
(B); V, viable cells, A, cells undergoing apoptosis,  showing chromatin condensation and nuclear fragmentation indicate apoptosis,  G, ghost cells. (C) 
DNA gel electrophoresis from B-CLL cells cultured in medium alone (lane 2) or with 10 ng/ml of IL-10 (lane 3); lane I, marker sizes (marker VIII, 
1114-19 bp). Giemsa staining and DNA gel electrophoresis were performed with the same B-CLL sample, after a 2-d culture. Figures are representative 
of experiments performed on five different B-CLL samples. 
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at day 3  (Table  1). 
The IL-10-induced apoptosis was further confirmed by mi- 
croscopic  examination of Giemsa-stained smears. As shown 
in Fig. 4 A, B-CLL cells cultured without IL-10 for 3 d dis- 
played an homogeneous morphology. In contrast, cells cul- 
tured with IL-10 displayed a considerable heterogeneity after 
staining, with three principal types: "V" for viable cells, "A" 
for apoptotic cells, and "G" for ghost cells. In fact, sorted 
viable cells (lower left quadrant of Fig. 3 B) yielded V cells 
of Fig. 4 B, while sorted cells incorporating Hoechst 33342 
undergoing apoptosis (lower right quadrant of Fig. 3 B) yielded 
A cells. Finally, cells incorporating propidium iodide of the 
upper quadrant yielded G cells. 
Typical "ladder" pattern of internucleosomal  DNA cleavage 
was observed on gel electrophoresis from DNA of B-CLL 
cells cultured for 3 d with IL-10 (Fig. 4 C, lane 3). A slight 
DNA fragmentation was obtained with B-CLL cells cultured 
without IL-10, reflecting spontaneous apoptosis (Fig.  4 C, 
lane 2). 
IL-10 promoted the B-CLL apoptosis in a dose-dependent 
manner, 50% of the maximal effect was obtained with 0.6 
ng/ml of IL-10 and optimal effect was obtained with 3 ng/ml 
of IL-10 (Fig. 5 A). The induction of B-CLL cell apoptosis 
was specific to IL-10,  as a neutralizing anti-IL-10 purified 
antibody inhibited it (Fig.  5 B). 
The in vitro survival of B-CLL cells has been shown ear- 
lier to be enhanced by addition of IL-4 (reference  16;  Fig. 
6 A), IFN-3,  (reference 17; Fig. 6 A) and anti-CD40 mAb 
(references  18,  19; Fig. 6 A). As shown on Fig. 6 B, these 
agents also prevented the B-CLL apoptosis induced by IL- 
10. Interestingly, IL-2, which per se had only marginal effects 
on the survival  of B-CLL cells, was able to counteract IL- 
10-induced cell death. 
IL-IO  Decreases the  Levels of Bcl-2  Protein  in  B-CLL 
Cells.  Studies on mechanisms controlling apoptosis have in- 
dicated a key role for protooncogene bcl-2 in prevention of 
apoptosis of lymphocytes (20), neuronal cells (21), and fibro- 
blasts (22).  Thus, Bcl-2  protein levels were determined in 
B-CLL cells by flow cytometry after permeabilization of cells 
with saponin and staining with a FITC-labeled anti-Bcl-2 
monoclonal antibody. Freshly isolated B-CLL cells expressed 
Bcl-2 protein in a unimodal fashion, at high level (Bcl-2hig  h) 
(Fig.  7 A). After a 4-d culture in medium alone,  74%  of 
the B-CLL cells expressed as much Bcl-2 as freshly isolated 
B-CLL cells (Bcl-2high), whereas 26% of the cells expressed 
low levels of Bcl-2  (Bcl-2  l~  (Fig.  7 B). Addition of IL-10 
to cultures resulted in a decrease of Bcl-2  expression,  with 
83% being Bd-2  l~  and 17% being Bcl-2hig  h. The mean per- 
centage of Bcl-2  l~  cells of seven samples  cultured for 3 d 
with IL-10, was 58%  _+ 26 (mean _+  SD), contrasting with 
38%  +  25 in cells cultured without IL-10 (p  =  0.018,  ac- 
cording to a Wilcoxon rank test). FACS  |  analysis performed 
on these samples cultured with IL-10 showed a mean of 50% 
+  29 of nonviable cells, including those incorporating ei- 
ther Hoechst 33342 or propidium iodide or both dyes. The 
percentage  of Bcl-2  l~  cells  was  correlated  with  the  per- 
Figure  5.  The effect  of IL-10 on B-CLL apoptosis is dose dependent 
and specific. 5  x  105 B-CLL  cells were cultured (.4) for 24 h without 
or with serial dilutions  of Ibl0; (B) for 24 h with IL-10 (10 ng/ml), or 
anti-IL-10 rabbit purified  polyclonal  antibody  (3 ~g/ml) or anti-C4 anti- 
body (3/~g/ml) as a control, or combination  of I1.-10 and anti-IL-10  anti- 
body or IL-10 and anti-C4 antibody. The proportion of apoptotic cells 
was determined  by FACS  |  analysis  after  staining  with Hoechst  33342 and 
propidium iodide. 
Figure  6.  Inhibition  of the Ibl0 driven apoptosis of B-CLL cells by 
Ib2, 1I.-4, IFN-% and anti-CD40. 5 x  10  s B-CLL  cells were incubated 
in 500 ~1 of  complete  medium  without (ill) or with (B) Ibl0 and without 
(medium) or with cytokines  (IL-2, 20 U/ml; IL-4, 100 U/ml; IFN-y, 500 
U/ml), or with anti-CD40 mAb 89 (0.5/zg/ml) and CDw32 transfected 
L cells (25,000/well). At day 3, percentages  of apoptosis were determined 
by flow  cytometry  as described earlier. Results  are expressed as mean -+ 
SD of three different  experiments. 
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Figure  7.  Bcl-2  expression in B-CLL cells treated by IL-10. Bcl-2 ex- 
pression in B-CLL cells  before (A) and after (B) 4-d culture in complete 
medium without (dashed  line) or with IL-IO  (plain line); dotted histograms 
(left) represent unmatched control antibody. 
centage of dead cells (p  =  0.026, according to a Fisher Z test). 
As shown in Fig. 8 B, representing the results pooled from 
three independent experiments,  the IL-10-induced decrease 
of Bcl-2 expression, observed at day 3, was prevented by ad- 
dition  of  IL-2,  IL-4,  IFN-y,  and  anti-CD40  antibody 
presented on CDw32 L cells (15).  These results are in line 
with the suppression of IL-10-mediated apoptosis of B-CLL 
cells, observed with those agents (Fig. 6). Note that anti-CD40 
activation  was able to prevent  the  spontaneous  decrease of 
the proportion  of Bcl-2  high cells  in cultures  of B-CLL cells 
without IL-10, while IL-2, IL-4, and IFN-3, were unable to 
do  so (Fig.  8 A). 
IL-IO Does Not Induce Apoptosis of  Non-Hodgkin's Lymphomas 
and Hairy Cell Leukemias B Cells.  We then wondered whether 
other malignant B cells would also undergo apoptosis in re- 
sponse to IL-10. Thus, malignant B cell samples from eight 
non-Hodgkin's lymphomas and three hairy ceil leukemias were 
cultured in complete medium with or without IL-IO. After 
3 d, cell viability was determined by Trypan blue exclusion 
Figure  8.  IL-2,  IL-4,  IFN-'y, and anti-CD40 activation sustain Bcl-2 
expression in IL-IO treated B-CLL cells. 5  x  10  s B-CLL ceils were in- 
cubated in 500/~1 of complete medium without (.4) or with (B) IL-10 
and without (medium) or with cytokines  (IL-2; 20 U/ml; IL-4, 100 U/ml; 
IFN-2/, 500 U/ml), or with anti-CD40 mAb 89 (0.5 #g/ml) and CDw32 
transfected L cells (25,000/well). At day 3, expression  of  Bcl-2 was deter- 
mined by flow cytometry  as described  in Materials and Methods. Results 
are expressed as mean _+  SD of three different experiments. 
and apoptosis was determined by FACS |  analysis after incu- 
bation with  propidium  iodide and  Hoechst 33342.  Before 
culture, expression of CD5, CD10, and surface Ig were de- 
termined on all samples tested. As shown in Table  1, results 
were compared with those obtained on a panel of eight B-CLL 
samples. In all cases, IL-10 decreased the viability and increased 
the apoptosis of the eight B-CLL samples (p  =  0.01). In con- 
trast, IL-10 failed to alter cell viability or to induce apoptosis 
of all the eight lymphoma samples (p  =  0.67), whatever their 
expression of CD5 and CD10 antigens.  Similarly,  the three 
hairy cell leukemia samples tested were not significantly in- 
duced to undergo  apoptosis in  response to  IL-10. 
Discussion 
Previous studies have demonstrated that B-CLL cells spon- 
taneously die from  apoptosis during  in vitro culture  (23), 
although it remains low compared to the important cell death 
observed with  normal  B cells (10%  vs.  35%,  respectively, 
after 24 h; mean of five experiments; our unpublished data). 
The spontaneous apoptosis of B-CLL cells was earlier found 
to be enhanced by glucocorticoids (16), Ca2 + ionophore and 
anti-IgM antibodies (24). In the present report, we demon- 
strate that IL-10 is also able to enhance apoptosis of B-CLL 
cells. This is indicated by: (a) flow cytometric analysis showing 
Hoechst 33342 incorporation;  (b) Giemsa staining,  showing 
cells with condensed chromatin;  and (c) gel electrophoresis, 
showing internucleosomal DNA fragmentation,  all charac- 
teristic of apoptosis.  Low concentrations oflL-10 (1-I0 ng/ml) 
induced B-CLL cells into successive steps toward death and 
10-fold this optimal concentration  (100 ng/ml)  did not re- 
sult in the recruitment  of a larger proportion  of apoptotic 
B-CLL cells. However, cells progressively entered into apop- 
tosis with time, ultimately resulting in the loss of cultures. 
It is not clear:  (a) why some cells of a given leukemic clone 
enter into apoptosis early in the culture while others do it 
later,  and (b) why some B-CLL samples are more susceptible 
to the apoptotic effect of IL-10 than others. It could possibly 
be related to the age of the B-CLL cells at the time of their 
isolation  from the patient,  or to their cell cycle. The level 
and promptness of sensitivity to IL-10 could not be related 
to a particular phenotype such as expression of slgD, CD23, 
CD39, CD38, and CD25. Nevertheless,  all B-CLL cells tested 
were found to enter apoptosis in response to IL-10, thus in- 
dicating an homogeneous response of this leukemic cell type. 
This property seems to be restricted to B-CLL cells, as malig- 
nant B cells from non-Hodgkin's lymphomas, expressing or 
not the CD5 antigen,  and hairy cell leukemias did not show 
increased cell death when cultured with IL-10. In this con- 
text, increased circulating IL-10 levels have been detected in 
sera of patients  suffering from non-Hodgkin's  lymphomas 
and the high levels of circulating IL-10 have been correlated 
to poor prognosis (25-27).  In HIV-associated lymphomas, 
this IL-10 production was ascribed to the neoplastic clone, 
thus suggesting a possible autocrine role in the proliferation 
of these cells (26), as demonstrated in EBV-transformed cell 
lines  (12,  28).  In contrast,  we did not  detect any IL-10 in 
the sera of 20 untreated B-CLL patients, whatever their clin- 
96  IL-10 Induces Apoptosis of B-Chronic Lymphocytic  Leukemia Cells ical stage (Sarfati,  M., J. Y. Blay, and A.-C.  Fluckiger, un- 
published results). 
75% of follicular lymphomas show a translocation t (14, 
18), which leads to the activation of the bcl-2 oncogene (29), 
which may explain  the lack of IL-10 induced apoptosis in 
those samples (Table  1). In fact, in the present study, IL-10 
was found to downregulate  the levels  of Bcl-2 protein  on 
B-CLL cells,  to an extent that  correlated with the level of 
induced apoptosis. The pooled results of three different B-CLL 
samples demonstrated a nonsignificant effect of IL-4 on the 
Bcl-2 expression by B-CLL cells,  a result contrasting  with 
a previous study (16).  In line with our results,  the lack of 
effect of IL-4,  Bcl-2 protein  expression  has  been recently 
reported in five B-CLL samples (30). However, Bcl-2 expres- 
sion in one of the three samples tested herein was significantly 
increased  in  response  to  IL-4  while  two  others  remained 
unaffected.  Such an heterogeneous regulation  of Bcl-2 ex- 
pression in B-CLL cells in response to IL-4 remains  to be 
explained. Nevertheless, IL-4 was found, in all cases, to coun- 
teract  the IL-10 induced decrease of Bcl-2 expression. 
IFN-% IL-2, and anti-CD40, which blocked IL-10 induced 
apoptosis, also prevented the downregulation  of Bcl-2 pro- 
tein induced by IL-10. Interestingly, IL-2 was able to totally 
overcome the apoptotic effects of IL-10. This was observed 
not only in cells that spontaneously synthesized DNA in re- 
sponse to IL-2, but also in samples that failed to do so. This 
is better explained by the capacity of IL-10 to upregulate the 
expression of high affanity IL-2 receptors on B-CLL cells (11). 
These IL-2 receptors will then permit to transmit  a survival 
signal to the B-CLL cells as was shown earlier with ionomycin- 
treated  normal  B lymphocytes (31).  This  further  indicates 
that  the survival signal provided by IL-2 prevails  over the 
apoptotic signal of IL-IO.  While a positive correlation be- 
tween the level of Bcl-2 protein expression and B-CLL cell 
apoptosis was observed, a more detailed analysis will be re- 
quired to determine the pathways of IL-10-induced B-CLL 
apoptosis. In particular,  it will be worthy to determine how 
IL-10 affects  the expression of bcl-x and  bax  genes,  which 
were recently reported to play a key role in the regulation 
of apoptotic cell death  (32,  33). 
IFN-3' was also found to inhibit the IL-10-induced apop- 
tosis of B-CLL cells. Previous studies have demonstrated that 
IFN-3' sustained B-CLL cell survival (17) and promoted their 
proliferation (34). Furthermore,  IFN-3' has been detected in 
sera of patients with B-CLL (17),  thus suggesting a direct 
role in the in vivo expansion of the leukemic done. As B-CLL 
cells have been shown to produce IFN-3, (16) and as IL-10 
has been shown to inhibit IFN-y production (35-36), it will 
be worth studying whether the effects of IL-10 on B-CLL 
cells  are  due to an alteration  of the secretion of IFN-y or 
any other autocrine cytokines such as TNF-ot (37). In vivo, 
the  direct  effect of IL-10  on  B-CLL cells  may be further 
strengthened  by its inhibitory  effect on the production  of 
IFN-3~ (35, 36). 
The IL-10-induced inhibition of viability observed with 
B-CLL cells contrasts with the stimulation of viability ob- 
served in normal resting murine B cells (38). Several reasons 
may account for this discrepancy, the most likely being the 
neoplastic status of the B-CLL cells.  Accordingly, our pre- 
liminary studies failed to detect increased apoptosis of normal 
tonsillar  CD5 +  B  cells  in  response  to  IL-10  but  further 
studies are required to determine whether other normal  B 
cell subpopulations may undergo increased apoptosis after ex- 
posure to IL-10. 
The finding that IL-10 induces apoptosis of B-CLL cells, 
increases the array of IL-10 activities and constitutes another 
example  of a proapoptotic  effect of cytokines,  as  recently 
demonstrated for the cytotoxic effect of TNF-ot (39-41). This 
contrasts  with  other cytokines,  such as GM-CSF or IL-3, 
that act as growth factors and whose removal results in cell 
apoptosis (42). 
In summary, we have shown that IL-10 induces apoptotic 
cell death of B-CLL cells, a finding that calls for considering 
IL-10 in the immunotherapy  of chemoresistant  B-CLL. 
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